In the recent study, the researchers used a combination blockade of PD-1 and CXCR4. They analyzed the efficacy of specifically blocking CXCR4 on standard anti–PD-1 immunotherapy in hepatocellular carcinoma models. Most previous studies and clinical trials tested...

A molecular platform for reprogramming immune responses has been designed by researchers from the Children’s Hospital of Philadelphia (CHOP) and Stanford University. TRACeR-I can be used to develop cancer treatments by either directly modifying immune cells, such as T...

A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial conducted by UT Southwestern...

The team at MD Anderson Proton Therapy Center continues to expand ways to use proton therapy to benefit patients. The team pioneered pencil beam proton therapy, also called scanning beam, and intensity modulated proton therapy (IMPT). We are one of the few centers...

This study aims to explore the expression characteristics of AKR1B10 in HCC and its correlation with clinicopathological features, survival prognosis, and tumor immune microenvironment, further investigating its role and potential regulatory mechanisms in HCC. Learn...

Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St. Jude Children's Research Hospital and The University of...

A faulty cancer gene helps tumors evade immunity by stopping tumor cells releasing message-containing cargoes called exosomes. These findings, published in eLife, provide what the editors say is fundamental insight into the underlying biology of hepatocellular...